Bayer has launched a health supplement business in the United States.
The company has announced that it has launched its first-ever US-based pharmacy business with two products that have been described as “the next generation of wellness products”.
The first product, called Alpha Plus, has been described by Bayer as a “next-generation of wellness supplements”.
The company will begin selling Alpha Plus in the US market in the third quarter of 2019.
The other product, which is not yet in development, is the next-generation Alpha, which has a different formula that has been developed specifically for health products.
“We are excited to bring this unique approach to the market, and the growth opportunity it offers to our customers and employees,” said John B. Cogley, president and chief executive officer of Bayer.
“These products will bring the most advanced and advanced health care to consumers, with the added benefit of lowering costs and providing superior customer service.”
The US market for Bayer products has been in a state of flux for a while now.
It has been very difficult to find products to compete with the likes of Merck, Johnson & Johnson and Eli Lilly, as the health care industry is undergoing a rapid shift to an increasingly biologics-based approach.
While there is still a lot of competition in the market for the Alpha Plus products, Bayer is the first company to offer an Alpha Plus line in the U.S. It will be selling its first Alpha Plus product, Alpha Plus 2, in the second quarter of 2020.
The second product, in a different vein, Alpha Pro, will be available in the fourth quarter of 2021.
The Alpha line will also be available from other companies.
“Our strategy for the coming year is to focus on our growth opportunities, including the next generation Alpha line,” said Bischoff.
“As the world becomes increasingly bioprocessed, the need for a robust, highly-sustainable, and affordable supply chain is paramount.
We will deliver a line of high-quality, affordable health supplements to meet the needs of the rapidly evolving marketplace.”
The company also announced that its acquisition of the Australian medical research and development company Aurora Pharma, which it acquired in November, has now expanded to include an acquisition of its American pharmaceutical company Alpha Labs, which makes the Alpha line of supplements.
Bischoffs statement in the company blog on Monday is all about the new products, including a health and wellness line called Alpha.
It also announced a partnership with the National Institutes of Health.
“Bayer has been one of the largest investors in Aurora Pharma and its scientific innovation initiatives, including its Alpha line, which will allow us to create a highly complementary and integrative health product portfolio that can deliver unparalleled value to our shareholders,” said Cogleys vice president and general counsel, David D. Bich.
“The combination of our two companies will create a fully integrated health product and nutrition portfolio that will be a key driver of our continued growth.”
Alpha Labs’ CEO, Alex S. Hoch, said in a statement that the agreement “is a strong first step toward our mission to transform health and wellbeing for every individual, and to create more value for all our shareholders through our investment in a diverse portfolio of companies.
We are excited about the synergy between our companies, and look forward to collaborating with our new partners to deliver a high-impact portfolio of high quality products that will drive innovation and create jobs in America.”
The announcement of the partnership with Alpha Labs is a bit of a tease, but it does provide some insight into how Alpha Labs plans to compete against Merck and Johnson & Johnson.
The two giants are known to be extremely aggressive in the health supplement market, which they have both tried to expand into.
Bayer, for example, has gone into the health supplements business in Australia and is now the largest private player in the country.
Johnson &amm, which bought Johnson &t in 2016, also has a large market share in the Australian health supplement marketplace, according to the Australian Business Traveller.
However, Bayer’s investment in Alpha Labs should help it compete with other health supplement companies.
Bayer is expected to announce its financial results for the year ending June 30, 2021.